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ABSTRACT: Dextrin-colistin conjugates have been developed with the aim of reducing clinical 
toxicity associated with colistin and improving targeting to sites of bacterial infection. This study 
investigated the in vitro ability of these dextrin-colistin conjugates to bind and modulate bacterial 
lipopolysaccharide (LPS), and how this binding affects its biological activity. These results 
showed that colistin, and ‘amylase-activated’ dextrin-colistin conjugate to a lesser extent, bound 
to LPS and induced significant conformational changes to its structure. In biological studies, both 
colistin and dextrin-colistin conjugate effectively inhibited LPS-induced hemolysis and TNFα 
secretion in a concentration-dependent manner, but only dextrin-colistin conjugate did not cause 
additive toxicity at higher concentrations. This study provides the first direct structural 
experimental evidence for the binding of dextrin-colistin conjugates and LPS, providing insight 
into the mode of action of dextrin-colistin conjugates. 
 
INTRODUCTION 
Infectious diseases account for millions of deaths worldwide annually, with high associated 
costs.1 Antibiotic chemotherapy is successfully used to treat the majority of Gram-negative 
infections, but antibiotic-induced shedding of endotoxic lipopolysaccharides (LPS) may result in 
systemic sepsis, with an associated mortality of 30-50%. Thus, eradication of bacterial infection 
does not always lead to a positive clinical outcome. We have previously described the first 
bioresponsive polymer conjugates to target the delivery of antimicrobials to sites of inflammation, 
using dextrin-colistin conjugates as a prototypical model.2 Colistin is an amphiphilic antibiotic 
which binds to Gram-negative bacterial cell membranes, resulting in cytoplasmic leakage and cell 
death. Colistin may, however, be associated with considerable nephro- and neurotoxicity in the 
immunocompromized patient, which limits its clinical use. These ‘nanoantibiotic’ polymer 
therapeutics are administered centrally but are locally activated at sites of infection by amylase, an 
enzyme found throughout the body (typical serum concentration 60-120 IU/L) but present at 
elevated concentrations at sites of bacterial infection/inflammation.3 This local activation 
improves antibiotic targeting to sites of infection, enables the release of free colistin (using 
Polymer masked-UnMasked Protein Therapy (PUMPT))4 and reduces clinical toxicity. 
An important property of colistin is its ability to bind bacterial LPS and block its toxic biological 
activities5 (Figure 1). The phase structure, conformation and aggregation behavior of bacterial LPS 
and its components (e.g. lipid A) have been extensively characterized by various physical 
methods.6-8 LPS is biologically active in its micellar form, and colistin disaggregation effectively 
neutralizes its endotoxic effects by disrupting the regular spacing of LPS fatty acid chains and 
binding in a 1:1 complex.9 Whilst the toxicity profile and antibacterial activity of the dextrin-
colistin conjugates has been described, nothing was known of its structural and functional 
interactions with LPS. In these studies, colistin-LPS complex formation, and potential LPS 
neutralization, was studied using small-angle neutron scattering (SANS), circular dichroism (CD) 
spectroscopy and turbidity assays to characterize the in vitro ability of the conjugates to bind and 
modulate bacterial LPS from Escherichia coli (E. coli), and determine how the degree of 
unmasking affected LPS binding. Parallel studies investigated in vitro inhibition of LPS-induced 
erythrocyte hemolysis and TNFα release from human kidney (HK-2) cells as a marker of LPS 
complex formation with colistin sulfate, colistimethate sodium (CMS) and dextrin-colistin 
conjugate. 
 
RESULTS 
Endotoxin binding. LPS caused significant scattering of neutrons, which was altered in the 
presence of colistin or unmasked dextrin-colistin conjugate at ≥10 mg/mL (Figure 2). The 
emergence of 2 peaks at Q = 0.06 and 0.11 Å-1 and a pronounced increase in scattering intensity 
at low Q was apparent when LPS was combined with colistin. These peaks did not change position 
with different colistin concentrations, although the intensity of the peaks varied, and was greatest 
with 10 mg/mL colistin. The two characteristic peaks were absent when LPS was pre-incubated 
with dextrin-colistin conjugate and there was a pronounced decrease in the data at low Q. Pre-
incubation of dextrin-colistin conjugate with amylase, however, induced a time-dependent 
increase in scattering intensity at low Q and the appearance of a peak at Q = 0.06 Å-1 at 50 mg/mL. 
Clearly the peaks are a result of the action of the colistin on the LPS structure.  
CD spectroscopy showed that colistin has a rigid cyclic secondary structure that was not altered 
by conjugation of dextrin or subsequent unmasking by amylase (Figure 3). When LPS was added 
to the antibiotic solutions, the CD spectra appeared to be equivalent to the sum of the CD signal 
of the individual components. Succinoylated dextrin had an unstructured conformation, which was 
unchanged in the presence of LPS (data not shown). 
Increasing turbidity was used as a marker of LPS aggregate formation with colistin, CMS or 
dextrin-colistin conjugate. When compared at equivalent colistin concentration, significant 
differences between the turbidity of colistin and CMS, dextrin-colistin (with or without amylase) 
or control were observed (Figure 3d). LPS binding of the dextrin-colistin conjugate was reduced 
to ~ 50% compared to free colistin; turbidity remained unaltered even after pre-incubation of the 
conjugate with amylase.  
Colistin, and CMS to a lesser extent, were able to inhibit the cleavage of chromogenic substrate 
by E. coli LPS (Figure 4). Neutralization of LPS by colistin required 20-fold more LPS to trigger 
Limulus amebocyte lysate gelation when compared to LPS in water, and was significantly greater 
than CMS (1 vs. 0.05 ng/mL, respectively). All dextrin-colistin conjugate samples gelled Limulus 
amebocyte lysate without the addition of LPS. Nevertheless, at the lower concentrations of LPS, 
unmasked conjugate was capable of binding more LPS than masked conjugate and there was a 
trend for increasing endotoxin binding after unmasking by amylase (6 h > 24 h > 0 h) (data not 
shown). 
In Vitro Inhibition of Endotoxin Activity. When HK-2 cells were treated with LPS alone or in 
the presence of colistin sulfate, CMS or ‘unmasked’ dextrin-colistin conjugate, there was little 
effect on LPS-induced TNFα release at low concentrations, but increased cytokine release was 
observed when colistin molar concentration exceeded that of LPS (Figure 5). However, at both 
LPS concentrations (10 and 100 ng/mL), dextrin-colistin conjugate inhibited LPS-induced TNFα 
release in a concentration-dependent manner above 5 and 50 µg/mL, respectively. 
Similarly, addition of colistin sulfate, CMS and dextrin-colistin conjugate inhibited endotoxin-
induced hemolysis of rat erythrocytes up to ~20 µg/mL (Figure 6). However, while higher 
concentrations of colistin and CMS caused increasing erythrocyte lysis, dextrin-colistin conjugate 
continued to inhibit hemolysis in a concentration-dependent manner. ‘Unmasked’ dextrin-colistin 
conjugate was unable to inhibit endotoxin-induced hemolysis and caused equivalent toxicity to 
colistin and CMS at higher concentrations. 
 
DISCUSSION 
A detailed understanding of the physicochemical properties and structure-activity relationships 
is vital to predict the behavior of polymer therapeutics in biological systems and ensure the design 
of safe and efficacious nanomedicines. The ability of colistin to bind and neutralize LPS is well 
documented, however little is known about how polymer conjugation affects the structural and 
biological properties of colistin. Whilst the antimicrobial activity of dextrin-colistin conjugates has 
been demonstrated in vitro,2 antibiotic treatment may induce LPS release from lysed bacteria, 
which may induce overreaction of the immune system and endotoxic shock. Therefore, these 
studies investigated whether dextrin-colistin conjugates (before and after amylase-‘unmasking’) 
could bind and neutralize released endotoxins. Dextrin-colistin conjugates used in these studies 
contained ~10% w/w colistin, of which < 2% was unbound, indicating multiple (typically 2) 
dextrin chains per colistin with several (typically 3) binding sites. The dextrin-colistin 
concentrations used in the SANS and CD spectroscopy studies refer to total conjugate; thus 
conjugate samples contained ~10x less colistin than the equivalent free drug samples. While this 
may affect the biological activity of the conjugates, it was deemed the most appropriate means of 
comparing the samples in these structural studies.  
The use of SANS to study evolving biological systems has been previously employed to 
investigate dextrin-phospholipase A2-triggered degradation of liposomes.10 Here, we examined 
the effect of dextrin conjugation and unmasking by amylase on the interaction of colistin with LPS. 
With a critical micelle concentration (CMC) of ~14 µg/mL,8,11 LPS readily micellizes at the 
concentrations used in these studies. These studies assumed, not unreasonably, that the SANS 
scattering is dominated by that of the LPS. The data revealed significant conformational 
rearrangement of LPS following incubation with both colistin sulfate and unmasked dextrin-
colistin conjugate (colistin > 24 h unmasked dextrin-colistin > 6 h unmasked dextrin-colistin) at 
≥10 mg/mL. This conformational rearrangement was evident in the emergence of the peaks 
indicative of a regular ordered structure. Similarly, marked differences between the aggregation of 
colistin and LPS, and that observed with dextrin-colistin conjugates were observed in both the 
turbidity and LAL assays. CD spectroscopy, however, did not show any substantial change in the 
secondary structure of colistin or dextrin-colistin conjugates (masked and unmasked) in the 
presence of LPS, indicating that aggregation did not induce an α-helical structure, presumably due 
to the rigidity of colistin’s cyclic structure. This has also been observed with polymyxin B, while 
WLBU2, a cationic amphiphilic peptide, became markedly helical in the presence of LPS, which 
the authors attribute to the ability of polymyxin B (but not WLBU2) to destabilize and disrupt LPS 
vesicles.12  
Molecular modelling has demonstrated that colistin exerts its anti-endotoxic effects by breaking 
up the supramolecular structure of LPS.9 The downturn in the SANS from LPS at low Q in the 
presence of colistin (50 mg/mL) is an indication of this neutralization effect, since LPS and colistin 
have been shown to bind at an LPS to colistin ratio of 5.2:1 (by weight).13 The regularity and 
clarity of the peaks in the SANS induced by colistin are commensurate with a spacing of 5 nm, 
suggestive of a bilayer stack. The 5 nm structures seen here are in good agreement with the size of 
lipid A bilayers, a component of LPS, found by Labischinski et al.6 in their SANS studies, and by 
Katowsky et al.14 in their molecular modelling and x-ray powder diffraction experiments of 
bacterial LPS. Both these studies demonstrated that lipid A and rough LPS (having a short O-
specific chain, like E. coli O26:B6 used here) are 2.4 nm and 2.8 nm long, respectively. This would 
indicate that the structures seen in these studies are from the LPS. This is further supported by 
Wallace et al.,15 who reported that colistin aggregates formed above 2.1 g/mL with a diameter 
of 2.07 ± 0.3 nm. 
Binding and structural data using several biophysical techniques, including isothermal titration 
calorimetry (ITC), fluorescent probes and nuclear magnetic resonance (NMR) spectroscopy, have 
indicated that the LPS-colistin interaction is a two-stage mechanism.16 First, the complex is 
stabilized by electrostatic charges between colistin’s positive charges and LPS’s negatively-
charged head groups. Subsequently, complexation is strengthened by hydrophobic interactions 
between the hydrophobic domains of the two molecules. Given that dextrin-colistin conjugation 
uses ~3 of colistin’s positively charged amine groups, it is unsurprising that masked conjugates 
have no effect on LPS structure. While ‘unmasked’ conjugates induced some conformational 
rearrangement of LPS, this was not as obvious as native colistin. This was not surprising since α-
amylase is an endoamylase that cleaves dextrin within the polyglucose chain, thus, ‘unmasked’ 
dextrin-colistin conjugates retain oligosaccharide fragments attached to colistin’s amine groups, 
which would reduce its cationic charge.  
Parallel studies investigated in vitro inhibition of LPS-induced erythrocyte lysis and TNFα release 
from human kidney cells as a marker of LPS aggregate formation with colistin or dextrin-colistin 
conjugate. Following systemic administration, dextrin-colistin conjugates are expected to remain 
in the bloodstream for an extended period, due to their macromolecular size, but would ultimately 
be excreted via the kidneys following amylase unmasking. Despite the negligible binding to 
bacterial LPS, the ability of dextrin-colistin conjugates to exert a protective effect from endotoxins 
on erythrocytes and human kidney cells was in keeping with previous studies showing that dextrin 
is able to effectively impede the hemolytic activity of drugs, such as zidovudine,17 and proteins, 
such as phospholipase A2.18 In these previous studies the effect was evident when zidovudine was 
covalently linked to dextrin or physically mixed with dextrin, providing further proof that dextrin 
acts by a cytoprotective mechanism. Moreover, dextrin conjugates (iodine-lithium-α-dextrin, 
ILαD) have been described with anti-endotoxin activity.19,20 These studies demonstrated that 
ILαD suppresses CD14 receptor expression, inhibits LPS-induced pro-inflammatory activation of 
monocytes and neutrophils, and increases tolerance to endotoxins.  
Polymyxin B-dextran 70 conjugates have been described that effectively inhibit LPS-induced 
TNFα production in vivo, Lake et al.21 proposed that polymyxin B-dextran 70 conjugates 
neutralize the pathogenic pharmacophore of endotoxin, citing unpublished studies corroborating 
its ability to bind to radiolabeled endotoxin. Interestingly, parallel studies employed polymyxin B 
conjugated to a 70,000 g/mol, dextran; yielding conjugates containing 3.8% w/w polymyxin B 
(equivalent to 2.1 polymyxin B per /dextran); with a markedly reduced antibiotic activity.22 In 
contrast, our dextrin-colistin conjugates contain 8,000 g/mol dextrin and 10.1% w/w colistin, 
equivalent to 1.6 dextrin chains per colistin, which may explain the difference in antibacterial 
activity.  
 
CONCLUSIONS 
These data clearly demonstrate physical differences in the LPS interaction of colistin and 
dextrin-colistin conjugates pre- and post-amylase unmasking. No change in the LPS structure was 
observed for dextrin-colistin conjugates, however, degradation of conjugates showed time-
dependent changes in LPS complex formation, that were more pronounced after prolonged 
incubation with amylase. Despite the inability of dextrin-colistin conjugates to bind to bacterial 
LPS, concentration-dependent inhibition of LPS-induced toxicity was evident, indicating that 
dextrin-colistin conjugates could represent effective neutralizers of endotoxin with application in 
the treatment of sepsis.  
 
EXPERIMENTAL SECTION 
Dextrin-colistin conjugate synthesis. Dextrin-colistin conjugate was synthesized and 
characterized using methods previously described.2 The dextrin-colistin conjugate used in these 
studies contained dextrin with 1.1 mol% succinoylation and had a molecular weight of 
approximately 9,000 g/mol (gel permeation chromatography (GPC) with pullulan standards) and 
a colistin content of approximately 10.1% w/w (bicinchoninic acid (BCA) assay) with < 3% free 
colistin (fast protein liquid chromatography (FPLC)). Purity of dextrin-colistin conjugates was ≥ 
95%. 
Small-angle neutron scattering measurements. To assess the colistin-induced disruption of 
LPS aggregates, LPS from E. coli 026:B6 (5) (10 mg/mL) (Sigma-Aldrich, U.K.) was incubated 
with succinoylated dextrin, colistin sulfate (Sigma-Aldrich, U.K.), dextrin-colistin conjugate or 
unmasked dextrin-colistin conjugate (0.01, 0.1, 1, 10, 50 mg/mL) in D2O (Sigma-Aldrich, U.K.) 
containing phosphate buffer (PBS) (Oxoid, U.K.) (3 h at 37 oC, pH 7.4) prior to analysis by SANS. 
‘Unmasked’ dextrin-colistin conjugates were prepared by incubation of dextrin-colistin conjugate 
(50 mg/mL in PBS) with α-amylase from human saliva (100 IU/L) (Sigma-Aldrich, U.K.) for 6 or 
24 h at 37 oC, then lyophilized and stored at -20 oC before reconstitution in D2O prior to analysis 
by SANS. 
SANS experiments were performed on the steady-state reactor source on the D22 diffractometer 
at the ILL, Grenoble. A Q = (4π/λ) sin(θ/2) range between 0.005 and 0.5 Å-1 was obtained by 
choosing two instrument settings at a constant neutron wavelength (λ) of 6 Å, the two sample-
detector distances were 2 m and 14 m respectively, both working with the detector being offset by 
40 cm with respect to the direct beam position on the detector. The samples were contained in 2 
mm path length, UV-spectrophotometer grade, quartz cuvettes (Hellma, U.K.) and mounted in 
aluminium holders on top of an enclosed, computer-controlled, sample chamber. Sample volumes 
were around 0.4 cm3. All experiments were conducted at 37 oC. Temperature control was achieved 
by using a thermostatic circulating bath pumping fluid through the base of the sample chamber, 
achieving a temperature stability of ± 0.2 oC. Experimental measuring times were approximately 
40 min. 
All scattering data were (a) normalized for the sample transmission, (b) background corrected 
using a quartz cell filled with D2O, and (c) corrected for the linearity and efficiency of the detector 
response using the instrument specific software package. Data was analyzed using SasView 2.2.0 
software. 
Circular Dichroism Spectroscopy. CD spectra were obtained using a Model 215 spectrometer 
(AVIV® Instrument Inc.) with a 1 mm path length quartz cell at 4 oC. Samples were dissolved in 
sodium fluoride (NaF) (100 mM) and potassium phosphate (KH2PO4) (20 mM) buffer at pH 7.4. 
Spectra of succinoylated dextrin, colistin sulfate, dextrin-colistin conjugate or ‘unmasked’ dextrin-
colistin conjugate (0.5 mg/mL) were obtained alone and following incubation with LPS (0.1 
mg/mL) (3 h at 37 oC, pH 7.4). ‘Unmasked’ dextrin-colistin conjugates were prepared by 
incubation of dextrin-colistin conjugate (10 mg/mL in NaF/KH2PO4 buffer) with amylase (100 
IU/L) for 24 h at 37 oC. The CD spectra were then obtained as described above. 
Turbidity Assay. A turbidimetric assay technique was used in which the binding of LPS to 
colistin results in precipitation of aggregates and increased turbidity. LPS was dissolved in pre-
warmed PBS buffer (1 mg/mL, 37 oC, pH 7.4) containing colistin sulfate, CMS (Colomycin® 
injection, Forest Laboratories UK Limited, U.K.), dextrin-colistin conjugate or ‘unmasked’ 
dextrin-colistin conjugate (4 mg/mL colistin equiv., 200 µL per well) and added to the wells of a 
96-well microtiter plate. Control samples contained only LPS dissolved in PBS. Plates were 
incubated at 37 oC throughout the experiment and absorbance was read at 625 nm at various 
timepoints (0, 15, 30, 60, 90, 120 min). Samples were assayed in triplicate and experiments were 
repeated once, and means of the results were calculated. 
‘Unmasked’ dextrin-colistin conjugates were prepared by incubation of dextrin-colistin 
conjugate (10 mg/mL in PBS buffer) with amylase (100 IU/L) for 24 h at 37 oC. The turbidity 
assay was then followed as described above. 
Limulus amebocyte lysate (LAL) Assay. Endotoxin neutralization was evaluated using a 
ToxinSensorTM chromogenic LAL endotoxin assay kit (GenScript, U.S.A.). LPS was dissolved in 
pyrogen free water (0-50 ng/mL) containing colistin sulfate, CMS, dextrin-colistin conjugate or 
‘unmasked’ dextrin-colistin conjugate (4 µg/mL colistin equiv., 100 µL) in pyrogen-free vials. 
Control samples contained only LPS dissolved in pyrogen-free water. Solutions were mixed well 
and incubated at 37 oC for 3 h. Reconstituted LAL (100 µL) was then added and the solution mixed 
well before incubation at 37 oC for 45 min. Next, reconstituted substrate solution (100 µL) was 
added to each vial, mixed well and incubated for a further 6 min. Finally, the reaction was 
terminated by addition of reconstituted stop solution and color stabilizers. Samples (100 µL) were 
pipetted into the wells of a 96-well microtiter plate (6 wells per sample) and absorption was read 
spectrophotometrically at 540 nm. The concentration of LPS producing 50% maximal absorption 
was taken as the ED50. 
‘Unmasked’ dextrin-colistin conjugates were prepared by incubation of dextrin-colistin 
conjugate (0.5 mg/mL in pyrogen free water) with amylase from human saliva (100 IU/L) for 6 h 
at 37 oC. The LAL assay was then followed as described above. 
Cell culture. Human kidney (HK-2) cells (immortalized proximal tubule epithelial cell line from 
normal adult human kidney) (Institute of Nephrology, Cardiff University, U.K.). were cultured in 
keratinocyte-serum free medium (K-SFM) medium with L-Glutamine, EGF and BPE (Invitrogen 
Life Technologies, U.K.) in standard culture conditions (37 oC, humidified air containing 5% 
CO2).  
Expression of TNFαHK-2 cells were seeded into sterile 96-well microtiter plates (2 x 105 
cells/ mL) in 0.1 mL/well media and allowed to adhere for 24 h. The medium was then removed 
and LPS (10 ng/mL) was added in the absence or presence of colistin sulfate, CMS or dextrin-
colistin conjugate (with or without amylase, 100 IU/L) (0.2 µm filter-sterilized) at different 
concentrations. After 24 h, microtiter plates were centrifuged (600 g, 10 min) and the supernatant 
was transferred to a clean 96-well plate and stored at -20 oC until determination of TNFα content. 
TNFα content in the cell supernatant was determined using a commercial human TNFα ELISA 
set (Thermo Scientific, U.K.) following the manufacturer’s protocol. Absorbance was measured 
at 450 nm using a microtiter plate reader. The absorbance values were expressed as mean ± SEM 
(n≥6) and used to calculate TNFα concentration in pg/mL (assay detection range 15-1000 pg/mL).  
Erythrocyte Lysis. Rat erythrocytes were prepared as previously described.18 Briefly, blood 
was obtained from a male Wistar rat (~250 g body weight) by cardiac puncture and collected in a 
heparin/lithium blood tube, in PBS (pH 7.4). Following centrifugation (1500 g, 10 min, 4 oC) and 
washing (x 2), the final erythrocyte pellet resuspended in PBS to produce a 2% w/v suspension. 
Subsequently, this erythrocyte suspension (100 µL) was added to a pre-incubated (3 h, 37 oC) 96-
well plate containing LPS (100 µg/mL final concentration) in the absence or presence of colistin 
sulfate, CMS, dextrin-colistin conjugate or ‘unmasked dextrin-colistin conjugate (0-500 µg/mL 
colistin equiv. final concentration). PBS was used as a negative control, and Triton X-100 (1% 
v/v) (Sigma-Aldrich, U.K.) was used to achieve 100% hemolysis. The plate was then incubated 
for 24 h at 37 oC, and then centrifuged at 1500 g for 10 min at 4 oC. The supernatant (100 µL) of 
each well was then carefully removed and placed into a clean 96-well plate and absorbance at 540 
nm read using a microtiter plate reader. The background hemolysis (PBS) was subtracted and the 
results were expressed as percentage hemoglobin released (± SEM).  
‘Unmasked’ dextrin-colistin conjugates were prepared by incubation of dextrin-colistin 
conjugate (2 mg/mL in PBS buffer) with amylase (100 IU/L) for 24 h at 37 oC. The hemolysis 
assay was then followed as described above. 
Statistics. The significance of the data was assessed using one-way analysis of variance 
(ANOVA) followed by Bonferroni’s post hoc test. Statistical significance was set at p < 0.05. 
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FIGURES  
Figure 1. Representation of the anti-endotoxin mechanism of dextrin-colistin conjugate, showing 
the unmasking strategy utilized to control delivery of colistin, and the effect of colistin on LPS 
aggregates. 
Figure 2. Small-angle neutron scattering from LPS (10 mg/mL in D2O) following incubation (3 h 
at 37 oC) with colistin sulfate, dextrin-colistin conjugate, and ‘unmasked’ dextrin-colistin 
conjugates at (a) 10 mg/mL and (b) 50 mg/mL. Panel c) shows the radii of gyration (Rg) calculated 
from the SANS data. 
Figure 3. CD spectra of a) colistin sulfate, b) dextrin-colistin conjugate, and c) ‘unmasked’ 
dextrin-colistin conjugate (0.5 mg/mL) in NaF (100 mM) and KH2PO4 (20 mM) buffer at pH 7.4, 
and following incubation (3 h at 37 oC) with LPS (0.1 mg/mL). Where sum = LPS signal + colistin 
signal and dif = LPS-colistin mixture signal – sum. Panel d) shows precipitation of LPS from E. 
coli (1 mg/mL) in the absence and presence of colistin sulfate, CMS, dextrin-colistin conjugate 
and ‘unmasked’ dextrin-colistin conjugate (4 mg/mL colistin equiv.). Data represents mean 
absorbance at 625 nm ± SEM, n = 6; * (p<0.01) and ** (p<0.001) indicate significance compared 
to LPS alone (control). 
Figure 4. Colorimetric detection of endotoxin following incubation of LAL with LPS from E. coli 
(0-50 ng/mL) in pyrogen-free water or pre-incubated for 3 h at 37 oC with colistin sulfate, CMS, 
dextrin-colistin conjugate and ‘unmasked’ dextrin-colistin conjugate (4 µg/mL colistin equiv.). 
Data represents mean absorbance at 540 nm ± SEM, n = 6; * (p<0.01) and ** (p<0.001) indicate 
significance compared to LPS alone (control); + (p>0.01) and ++ (p>0.001) indicate significance 
compared to dextrin-colistin conjugate. 
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Figure 5. Inhibition of LPS-induced (a) 10 ng/mL and (b) 100 ng/mL) TNFα release from HK-2 
cells following incubation with colistin sulfate, CMS, dextrin-colistin conjugate and dextrin-
colistin + amylase at 0-1000 µg/mL colistin equiv. (24 h incubation). Panel a) shows cell response 
to 10 ng/mL LPS and panel b) shows cell response to 100 ng/mL LPS. Data represents mean 
percentage TNFα release ± SD, n = 3; * (p<0.05), ** (p<0.01) and *** (p<0.001) indicate 
significance compared to LPS alone (control).  
Figure 6. Inhibition of LPS-induced (E. coli 026:B6, 100 µg/mL) hemolysis (24 h incubation) of 
rat erythrocytes following pre-incubation with colistin sulfate, CMS, dextrin-colistin conjugate 
and ‘unmasked’ dextrin-colistin conjugate for 3 h at 37 oC. Data represents mean percentage 
hemoglobin release ± SEM, n = 9; * (p<0.05) and ** (p<0.001) indicate significance compared to 
LPS alone (control). 
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